Roche Holding AG (RHHBF)
USD 303.32
(0.0%)
USD 303.32
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 11.49 Billion CHF | -7.43% |
| 2022 | 12.42 Billion CHF | -10.83% |
| 2021 | 13.93 Billion CHF | -2.55% |
| 2020 | 14.29 Billion CHF | 5.91% |
| 2019 | 13.49 Billion CHF | 28.54% |
| 2018 | 10.5 Billion CHF | 21.63% |
| 2017 | 8.63 Billion CHF | -9.85% |
| 2016 | 9.57 Billion CHF | 8.04% |
| 2015 | 8.86 Billion CHF | -5.03% |
| 2014 | 9.33 Billion CHF | -16.41% |
| 2013 | 11.16 Billion CHF | 18.43% |
| 2012 | 9.42 Billion CHF | 0.9% |
| 2011 | 9.34 Billion CHF | 7.81% |
| 2010 | 8.66 Billion CHF | 11.33% |
| 2009 | 7.78 Billion CHF | -13.21% |
| 2008 | 8.96 Billion CHF | -8.11% |
| 2007 | 9.76 Billion CHF | 23.87% |
| 2006 | 7.88 Billion CHF | 33.04% |
| 2005 | 5.92 Billion CHF | -10.34% |
| 2004 | 6.6 Billion CHF | 115.25% |
| 2003 | 3.06 Billion CHF | 176.23% |
| 2002 | -4.02 Billion CHF | -208.9% |
| 2001 | 3.69 Billion CHF | -57.25% |
| 2000 | 8.64 Billion CHF | 50.02% |
| 1999 | 5.76 Billion CHF | 31.24% |
| 1998 | 4.39 Billion CHF | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 3.12 Billion CHF | 0.0% |
| 2024 Q1 | 3.12 Billion CHF | -28.25% |
| 2023 FY | 11.49 Billion CHF | -7.43% |
| 2023 Q3 | 2.18 Billion CHF | -69.45% |
| 2023 Q4 | 4.36 Billion CHF | 100.0% |
| 2023 Q2 | 7.13 Billion CHF | 100.0% |
| 2023 Q1 | 3.56 Billion CHF | -8.29% |
| 2022 FY | 12.42 Billion CHF | -10.83% |
| 2022 Q4 | 3.89 Billion CHF | 100.0% |
| 2022 Q1 | 4.26 Billion CHF | -30.39% |
| 2022 Q2 | 8.53 Billion CHF | 100.0% |
| 2022 Q3 | 1.94 Billion CHF | -77.19% |
| 2021 Q1 | 3.9 Billion CHF | -37.23% |
| 2021 FY | 13.93 Billion CHF | -2.55% |
| 2021 Q3 | 3.06 Billion CHF | -60.74% |
| 2021 Q4 | 6.12 Billion CHF | 100.0% |
| 2021 Q2 | 7.8 Billion CHF | 100.0% |
| 2020 FY | 14.29 Billion CHF | 5.91% |
| 2020 Q1 | 4.03 Billion CHF | -17.19% |
| 2020 Q2 | 8.07 Billion CHF | 100.0% |
| 2020 Q3 | 3.1 Billion CHF | -61.53% |
| 2020 Q4 | 6.21 Billion CHF | 100.0% |
| 2019 Q4 | 4.87 Billion CHF | 100.0% |
| 2019 Q1 | 4.3 Billion CHF | 170.1% |
| 2019 Q2 | 4.3 Billion CHF | 0.0% |
| 2019 FY | 13.49 Billion CHF | 28.54% |
| 2019 Q3 | 2.43 Billion CHF | -43.4% |
| 2018 Q1 | 3.65 Billion CHF | 131.59% |
| 2018 FY | 10.5 Billion CHF | 21.63% |
| 2018 Q4 | 1.59 Billion CHF | 0.0% |
| 2018 Q3 | 1.59 Billion CHF | -56.34% |
| 2018 Q2 | 3.65 Billion CHF | 0.0% |
| 2017 Q2 | 2.73 Billion CHF | 0.0% |
| 2017 Q1 | 2.73 Billion CHF | 30.47% |
| 2017 FY | 8.63 Billion CHF | -9.85% |
| 2017 Q4 | 1.57 Billion CHF | 0.0% |
| 2017 Q3 | 1.57 Billion CHF | -42.38% |
| 2016 Q1 | 2.68 Billion CHF | 45.0% |
| 2016 FY | 9.57 Billion CHF | 8.04% |
| 2016 Q2 | 2.68 Billion CHF | 0.0% |
| 2016 Q4 | 2.09 Billion CHF | 0.0% |
| 2016 Q3 | 2.09 Billion CHF | -21.94% |
| 2015 FY | 8.86 Billion CHF | -5.03% |
| 2015 Q1 | 2.57 Billion CHF | 35.67% |
| 2015 Q4 | 1.85 Billion CHF | 0.0% |
| 2015 Q3 | 1.85 Billion CHF | -28.04% |
| 2015 Q2 | 2.57 Billion CHF | 0.0% |
| 2014 Q3 | 1.89 Billion CHF | -31.34% |
| 2014 FY | 9.33 Billion CHF | -16.41% |
| 2014 Q4 | 1.89 Billion CHF | 0.0% |
| 2014 Q2 | 2.76 Billion CHF | 0.0% |
| 2014 Q1 | 2.76 Billion CHF | 5.94% |
| 2013 FY | 11.16 Billion CHF | 18.43% |
| 2013 Q2 | 2.97 Billion CHF | 0.0% |
| 2013 Q3 | 2.61 Billion CHF | -12.09% |
| 2013 Q4 | 2.61 Billion CHF | 0.0% |
| 2013 Q1 | 2.97 Billion CHF | 0.0% |
| 2012 FY | 9.42 Billion CHF | 0.9% |
| 2011 FY | 9.34 Billion CHF | 7.81% |
| 2010 FY | 8.66 Billion CHF | 11.33% |
| 2009 FY | 7.78 Billion CHF | -13.21% |
| 2008 FY | 8.96 Billion CHF | -8.11% |
| 2007 FY | 9.76 Billion CHF | 23.87% |
| 2006 FY | 7.88 Billion CHF | 33.04% |
| 2005 FY | 5.92 Billion CHF | -10.34% |
| 2004 FY | 6.6 Billion CHF | 115.25% |
| 2003 FY | 3.06 Billion CHF | 176.23% |
| 2002 FY | -4.02 Billion CHF | -208.9% |
| 2001 FY | 3.69 Billion CHF | -57.25% |
| 2000 FY | 8.64 Billion CHF | 50.02% |
| 1999 FY | 5.76 Billion CHF | 31.24% |
| 1998 FY | 4.39 Billion CHF | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AstraZeneca PLC | 5.95 Billion USD | -93.081% |
| Bristol-Myers Squibb Company PFD CONV 2 | 8.02 Billion USD | -43.277% |
| CSPC Pharmaceutical Group Limited | 830.91 Million USD | -1283.774% |
| Clarus Therapeutics Holdings, Inc. | -56.51 Million USD | 20446.121% |
| Novartis AG | 14.85 Billion USD | 22.572% |
| PT Kalbe Farma Tbk. | 179.7 Million USD | -6298.245% |